Spots Global Cancer Trial Database for advanced solid tumor
Every month we try and update this database with for advanced solid tumor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Intratumoral Administration of Oncolytic Virus Injection (RT-01) in Patients With Advanced Solid Tumors | NCT05205408 | Advanced Solid ... | Oncolytic Virus... | 18 Years - | First Affiliated Hospital Bengbu Medical College | |
| Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors | NCT06054932 | Advanced Solid ... | LK101 injection LK101 injection | 18 Years - 75 Years | Beijing Likang Life Science and Tech Co., Ltd. | |
| Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma | NCT00861783 | Hepatoma Advanced Solid ... | irinotecan and ... oxaliplatin and... | 18 Years - | Traws Pharma, Inc. | |
| A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors | NCT06139211 | Advanced Solid ... | JS015 Toripalimab Paclitaxel Irinotecan Capecitabine Oxaliplatin Bevacizumab Fluorouracil Leucovorin Gemcitabine Albumin-Bound P... | 18 Years - 75 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors | NCT04761601 | Advanced Solid ... | UCT-01-097 Gemcitabine Paclitaxel | 18 Years - | 1200 Pharma, LLC | |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1 | NCT04418141 | Advanced Solid ... B Cell Lymphoma | CN1 | 18 Years - 75 Years | Curon Biopharmaceutical (Australia) Co Pty Ltd | |
| Meaning-Centered Pain Coping Skills Training | NCT04431830 | Advanced Solid ... Pain | Meaning-Centere... | 18 Years - | Duke University | |
| A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects | NCT04457180 | Advanced Solid ... | Apatinib Mesyla... Repaglinide Bupropion | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas | NCT05279300 | Advanced Solid ... Advanced Lympho... | CS5001 | 18 Years - | CStone Pharmaceuticals | |
| A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors | NCT05821777 | Advanced Solid ... | LB101 | 18 Years - | Centessa Pharmaceuticals plc | |
| A Phase I Study of RGT-264 in Subjects With Advanced Solid Tumors | NCT05764915 | Advanced Solid ... | RGT-264 phospha... | 18 Years - 80 Years | Regor Pharmaceuticals Inc. | |
| A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors | NCT04941339 | Advanced Solid ... | MRG002 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| A Study of IMC008 for Advanced Solid Tumors | NCT05837299 | Advanced Solid ... | IMC008 | 18 Years - 70 Years | Changhai Hospital | |
| Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors | NCT05505877 | Advanced Solid ... | BR790+Tislelizu... | 18 Years - 75 Years | Shanghai Gopherwood Biotech Co., Ltd. | |
| Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies | NCT04383938 | Bladder Cancer Gastric Cancer Non Small Cell ... NSCLC Urothelial Carc... Advanced Solid ... | APR-246 (eprene... | 18 Years - | Aprea Therapeutics | |
| Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients With CLDN18.2-positive Advanced Solid Tumors | NCT06084286 | Advanced Solid ... | Dual-targeting ... | 18 Years - 75 Years | Sichuan University | |
| STAT3 Inhibitor for Solid Tumors | NCT00955812 | Advanced Cancer Solid Tumor | OPB-31121 | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab | NCT05378425 | Cancer Tumor, Solid Advanced Solid ... Metastatic Canc... Locally Advance... | NTX-1088 Pembrolizumab | 18 Years - | Nectin Therapeutics Ltd | |
| Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors. | NCT05831995 | Advanced Solid ... RAS Mutation RAF Mutation NF1 Mutation | ABM-168 | 18 Years - | ABM Therapeutics Corporation | |
| A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors | NCT05381935 | Advanced Solid ... | ES014 ES014 | 18 Years - | Elpiscience Biopharma, Ltd. | |
| A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations | NCT05372120 | Advanced Solid ... | ICP-192 | 18 Years - | Beijing InnoCare Pharma Tech Co., Ltd. | |
| Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors | NCT05156203 | Advanced Solid ... Lymphoma | T-1301 Capsules | 20 Years - | Taivex Therapeutics Corporation | |
| Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca | NCT03919292 | Solid Tumor, Ad... | Neratinib Divalproex Sodi... | 18 Years - | Virginia Commonwealth University | |
| Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy | NCT03217669 | Advanced Solid ... Non-small Cell ... | Epacadostat sirolimus | 18 Years - | University of Kansas Medical Center | |
| The Safety and Efficacy of TWP-101 in Patients With Advanced Solid Tumor | NCT04871347 | Advanced Solid ... | TWP-101 | 18 Years - 75 Years | Shandong TheraWisdom Biopharma Co., Ltd. | |
| Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors | NCT05915481 | Advanced Solid ... Stereotactic Bo... Immune Checkpoi... Safety Efficacy | Cadonilimab Stereotactic bo... | 18 Years - 75 Years | Peking University Third Hospital | |
| A Study of BRY805 in Participants With Advanced Solid Tumors | NCT06289894 | Advanced Solid ... | BRY805 injectio... | 18 Years - | BioRay Pharmaceutical Co., Ltd. | |
| Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1. | NCT03666273 | Advanced Solid ... Head and Neck S... | Bapotulimab (BA... Bapotulimab (BA... | 18 Years - | Bayer | |
| Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies | NCT00449280 | Advanced Solid ... | Sorafenib Rapamycin Rapamycin | 18 Years - | University of Chicago | |
| Study of ART6043 in Advanced/Metastatic Solid Tumors Patients | NCT05898399 | Advanced Solid ... Metastatic Soli... | ART6043 Olaparib Niraparib Olaparib Niraparib | 18 Years - | Artios Pharma Ltd | |
| TIL for Patients With Advanced Solid Tumor | NCT06334783 | Advanced Solid ... | Autologous tumo... | 18 Years - 75 Years | Hervor Therapeutics | |
| First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors | NCT04505839 | Advanced Solid ... | STP1002 | 18 Years - | ST Pharm Co., Ltd. | |
| Study to Investigate DRP-104 in Adults With Advanced Solid Tumors | NCT04471415 | Advanced Solid ... Non Small Cell ... | DRP-104 atezolizumab | 18 Years - | Dracen Pharmaceuticals, Inc. | |
| A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients. | NCT06298058 | Advanced Solid ... | SIBP-A13 formul... | 18 Years - 75 Years | Shanghai Institute Of Biological Products | |
| Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | NCT04140526 | Non Small Cell ... Advanced Solid ... Metastatic Mela... Metastatic Head... Metastatic Rena... Metastatic Colo... Sarcomas Metastatic Pros... Ovarian Cancer Small Cell Lung... Metastatic Brea... Pancreas Cancer Gastric Cancer Esophageal Canc... Gastroesophagea... Cervical Cancer Adenoid Cystic ... Salivary Gland ... Urothelial Carc... | ONC-392 Pembrolizumab Docetaxel | 18 Years - | OncoC4, Inc. | |
| A Safety Study of YQ23 in Advanced Solid Tumors Patients | NCT04513067 | Advanced Solid ... | YQ23 Pembrolizumab | 18 Years - | New Beta Innovation Limited | |
| A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors | NCT04947033 | Advanced Solid ... | TJ210001 Inject... | 18 Years - | I-Mab Biopharma US Limited | |
| A Study of NBL-028 in Patients With Advanced Solid Tumors | NCT06223256 | Advanced Solid ... | NBL-028 | 18 Years - | NovaRock Biotherapeutics, Ltd | |
| TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers | NCT04485013 | Cancer | TTX-080 TTX-080 pembrolizumab cetuximab | 18 Years - | Tizona Therapeutics, Inc | |
| Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours | NCT04855435 | Advanced Solid ... | MBS8(1V270) | 18 Years - | MonTa Biosciences ApS | |
| A Study of BPI-460372 in Advanced Solid Tumor Patients | NCT05789602 | Advanced Solid ... | BPI-460372 | 18 Years - | Betta Pharmaceuticals Co., Ltd. | |
| A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors | NCT04914286 | Advanced Solid ... | GFH018 Toripalimab | 18 Years - 75 Years | Genfleet Therapeutics (Shanghai) Inc. | |
| Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | NCT05737706 | Solid Tumor Advanced Solid ... Non-small Cell ... Colo-rectal Can... Pancreatic Aden... | MRTX1133 | 18 Years - | Mirati Therapeutics Inc. | |
| A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors | NCT05892718 | Advanced Solid ... Refractory Non-... | HCB101 | 18 Years - | FBD Biologics Limited | |
| Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion | NCT05245500 | Mesothelioma Non Small Cell ... Malignant Perip... Solid Tumor Pancreatic Aden... Advanced Solid ... | MRTX1719 | 18 Years - | Mirati Therapeutics Inc. | |
| First in Human Study of TORL-3-600 in Participants With Advanced Cancer | NCT05948826 | Advanced Solid ... Colorectal Canc... | TORL-3-600 | 18 Years - | TORL Biotherapeutics, LLC | |
| A Study of DSP107 Alone and in Combination With Atezolizumab for Patients With Advanced Solid Tumors | NCT04440735 | Advanced Solid ... Non Small Cell ... Colorectal Canc... | DSP107 Atezolizumab | 18 Years - | Kahr Medical | |
| A Study of CBP-1008 in Patients With Advanced Solid Tumor | NCT04740398 | Advanced Solid ... | CBP-1008 | 18 Years - 70 Years | Coherent Biopharma (Suzhou) Co., Ltd. | |
| Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors | NCT05505877 | Advanced Solid ... | BR790+Tislelizu... | 18 Years - 75 Years | Shanghai Gopherwood Biotech Co., Ltd. | |
| Subjects With Advanced or Metastatic Solid Tumor Malignancies | NCT05474859 | Metastatic Soli... Advanced Solid ... | XT-0528 | 18 Years - | Xenthera, Inc. | |
| A Study of HG381 Administered to Patients With Advanced Solid Tumors | NCT04998422 | Advanced Solid ... | HG381 | 18 Years - | HitGen Inc. | |
| Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma | NCT00861783 | Hepatoma Advanced Solid ... | irinotecan and ... oxaliplatin and... | 18 Years - | Traws Pharma, Inc. | |
| ARQ 501 in Combination With Docetaxel in Patients With Cancer | NCT00099190 | Carcinoma | ARQ 501 | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Irinotecan Hydrochloride Liposome Injection (LY01610) For Advanced Solid Tumors | NCT04088604 | Advanced Solid ... | LY01610 ( Irino... LY01610 ( Irino... Irinotecan Hydr... | 18 Years - 70 Years | Luye Pharma Group Ltd. | |
| A Study to Investigate FP002 in Subjects With Advanced Malignancies | NCT05982080 | Advanced Solid ... | FP002 Injection | 18 Years - | Guangdong Fapon Biopharma Inc. | |
| PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors | NCT06078670 | Advanced Solid ... | CVL218 | 18 Years - 75 Years | Fujian Cancer Hospital | |
| Study of LP-184 in Patients With Advanced Solid Tumors | NCT05933265 | Advanced Solid ... | LP-184 | 18 Years - | Lantern Pharma Inc. | |
| A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies | NCT04772989 | Advanced Solid ... Non Small Cell ... Melanoma Cervical Cancer Multiple Myelom... Lymphoma, Non-H... Diffuse Large B... Gastric Cancer Gastroesophagea... Esophageal Canc... | AB308 Zimberelimab | 18 Years - | Arcus Biosciences, Inc. | |
| An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia | NCT05226468 | Advanced Solid ... Relapsed AML Refractory AML | NEI-01 | 18 Years - | New Epsilon Innovation Limited | |
| Phase I Study of QLS1103 in Subjects With Advanced Solid Tumors | NCT05884801 | Advanced Solid ... | QLS1103 | 18 Years - | Qilu Pharmaceutical Co., Ltd. | |
| Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor | NCT03239145 | Advanced Solid ... | Pembrolizumab Trebananib | 18 Years - | Dana-Farber Cancer Institute | |
| A Study to Evaluate the Safety and Therapeutic Activity of GI-102 in Patients With Advanced Solid Tumors | NCT05824975 | Advanced Solid ... Metastatic Soli... | GI-102 GI-102 | 18 Years - | GI Innovation, Inc. | |
| A Phase I Study of Famitinib Malate in Patients With Solid Tumor | NCT01762280 | Advanced Solid ... | Famitinib Malat... | 18 Years - 65 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Study of M4344 in Combination With Niraparib | NCT04655183 | Advanced Solid ... Breast Cancer | Niraparib M4344 Niraparib M4344 Niraparib Niraparib | 18 Years - | EMD Serono | |
| Phase 1 Study of Oral TP-1454 | NCT04328740 | Advanced Solid ... Anal Cancer | TP-1454 monothe... | 18 Years - | Sumitomo Pharma America, Inc. | |
| FIH XON7 in Advanced/Metastatic Solid Tumors | NCT06154291 | Advanced Solid ... Metastatic Canc... | XON7 | 18 Years - | Xenothera SAS | |
| A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors | NCT02133625 | Advanced Solid ... Metastatic Soli... | carboplatin pioglitazone | 18 Years - | Dana-Farber Cancer Institute | |
| A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer | NCT06005740 | Advanced Solid ... Hepatocellular ... | TORL-4-500 | 18 Years - | TORL Biotherapeutics, LLC | |
| First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors. | NCT06240546 | Advanced Solid ... | LPM6690176 | 18 Years - 75 Years | Luye Pharma Group Ltd. | |
| A Study of QLF3108 in Participants With Advanced Solid Tumor | NCT06019013 | Advanced Solid ... | QLF3108 | 18 Years - | Qilu Pharmaceutical Co., Ltd. | |
| M9466 as Single Agent or in Combination With Tuvusertib in Advanced Solid Tumors (DDRiver 501) | NCT06421935 | Advanced Solid ... | M9466 Tuvusertib | 18 Years - | EMD Serono | |
| Phase I Study of the BBP-398 in Patients With Advance Solid Tumors | NCT05621525 | Advanced Solid ... Advanced or Met... | BBP-398 | 18 Years - 99 Years | LianBio LLC | |
| A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors | NCT06237881 | Advanced Solid ... Melanoma Lung Neoplasms Head and Neck N... | KSQ-001EX Interleukin-2 Cyclophosphamid... Fludarabine | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors. | NCT05888857 | Advanced Solid ... | MEDI5752 | 18 Years - | Institut Bergonié | |
| Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy | NCT04106167 | Advanced Solid ... Lymphoma Gastric Cancer Colorectal Canc... Head and Neck C... Squamous Cell C... EGFR Positive S... HER2-positive B... Hepatocellular ... Small-cell Lung... Renal Cell Carc... Pancreas Cancer Melanoma NSCLC Urothelial Carc... Cervical Cancer Microsatellite ... Merkel Cell Car... | Allogeneic natu... | 18 Years - | Fate Therapeutics | |
| Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment | NCT05101265 | Advanced Solid ... Hepatic Impairm... | Lurbinectedin Lurbinectedin | 18 Years - | PharmaMar | |
| First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors | NCT03758001 | Advanced Solid ... | IBI101 IBI101 Sintilimab | 18 Years - 75 Years | Innovent Biologics (Suzhou) Co. Ltd. | |
| A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab | NCT05259709 | Advanced Solid ... Metastatic Soli... | 89Zr˗DFO˗REGN50... cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208) | NCT04003623 | Advanced or Met... FGFR Mutations FGFR Translocat... | Pemigatinib | 18 Years - | Incyte Corporation | |
| JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation | NCT05002270 | Advanced Solid ... NSCLC CRC | JAB-21822 (KRAS... JAB-21822 (KRAS... JAB-21822 (KRAS... Cetuximab (EGFR... | 18 Years - | Jacobio Pharmaceuticals Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
